Claims for Patent: 10,507,265

Summary for Patent: 10,507,265

Title:	Cancellous bone product including viable osteogenic cells
Abstract:	A bone implant comprising cancellous bone that is essentially free of blood cells, and which has been treated with at least a loosening agent, such as collagenase and/or a digestive enzyme, for a time and at a concentration to loosen the osteogenic cells in the cancellous bone matrix. The osteogenic cells in the matrix are viable cells. The treatment of the cancellous bone with at least one loosening agent enables the osteogenic cells to be more available for carrying out their osteogenic function and to provide for an increased rate of bone formation.
Inventor(s):	Williams; Michelle LeRoux (Laurel, MD), Mills; Charles Randal (Finksburg, MD), Monroy; Rodney (Aberdeen, MD)
Assignee:	NuVasive, Inc. (San Diego, CA)
Application Number:	15/596,237
Patent Claims:	1. A bone product, comprising: cancellous bone matrix essentially free of hematopoietic cells, said cancellous bone matrix including native, viable osteogenic cells; demineralized bone matrix; and a cryopreservative; wherein the cancellous bone matrix has been treated to partially digest the cancellous bone matrix and enhance availability of the native, viable osteogenic cells for carrying out their osteogenic function. 2. The bone product of claim 1, wherein the cancellous bone matrix and the cryopreservative are combined in a sealed container. 3. The bone product of claim 1, wherein the bone product is frozen. 4. The bone product of claim 3, wherein upon thawing of the bone product, at least 70% of the native, viable osteogenic cells are viable. 5. The bone product of claim 4, wherein the bone product when frozen are stored in the cryopreservative at -80 degrees Celsius.+-.5 Celsius for a period of seventeen days. 6. The bone product of claim 1, wherein the bone product has been treated with at least one of an antibiotic or at least one of an antimycotic. 7. The bone product of claim 1, wherein the bone product comprises cancellous bone chips. 8. The bone product of claim 1, wherein the bone product comprises milled cancellous bone. 9. The bone product of claim 1 is an allograft bone product. 10. A bone product, comprising: treated cancellous bone essentially free of hematopoeitic cells, said cancellous bone matrix including native, viable osteogenic cells; untreated bone; and a cryopreservative; wherein the cancellous bone matrix has been treated with a loosening agent to enhance availability of the native, viable osteogenic cells for carrying out their osteogenic function. 11. The bone product of claim 10, wherein the untreated bone comprises at least one of allograft bone chips, fragments, and powder. 12. The bone of claim 10, wherein the treated cancellous bone matrix, untreated bone and the cryopreservative are combined in a sealed container. 13. The bone product of claim 10, wherein the loosening agent is a collagenase. 14. The bone product of claim 10, wherein the loosening agent is a digestive enzyme. 15. The bone product of claim 10, wherein the treated cancellous bone matrix comprises cancellous bone chips. 16. The bone product of claim 10, wherein the treated cancellous bone matrix comprises milled cancellous bone.

Details for Patent 10,507,265

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2026-05-08